Advanced

The GABAA Receptor as Target for Novel Heterocyclic Compounds

Nilsson, Jakob LU (2008)
Abstract
Ligands for the benzodiazepine-binding site of the GABAA receptor can belong to structurally diverse classes of compounds including, in spite of the name of the binding site, many non-benzodiazepine structures. The GABAA receptor is a ligand-gated ion channel assembled of five subunits from eight different classes with multiple isoforms. The physiological effect elicited by benzodiazepines is believed to depend particularly on the isoform of the α-subunit. In this study new heterocyclic ligands were designed and synthesized from a pharmacophore model of the benzodiazepine-binding site partly developed in this study. The novel heterocyclic benzodiazepine receptor ligands synthesized include 4-quinolones, aza flavones, triazoloquinazolines,... (More)
Ligands for the benzodiazepine-binding site of the GABAA receptor can belong to structurally diverse classes of compounds including, in spite of the name of the binding site, many non-benzodiazepine structures. The GABAA receptor is a ligand-gated ion channel assembled of five subunits from eight different classes with multiple isoforms. The physiological effect elicited by benzodiazepines is believed to depend particularly on the isoform of the α-subunit. In this study new heterocyclic ligands were designed and synthesized from a pharmacophore model of the benzodiazepine-binding site partly developed in this study. The novel heterocyclic benzodiazepine receptor ligands synthesized include 4-quinolones, aza flavones, triazoloquinazolines, isoxazoloquinolones, pyrazoloquinolones, isothiazoloquinolones and isothiazolyl amides. All of these compound classes were active in vitro on the GABAA receptor with the 4-quinolone 72 displaying the highest affinity (Ki = 0.048 nM) so far reported. The 4-quinolones and the aza flavones all displayed selectivity for α1- versus α2- and α3-containing receptors, ranging from 2 to 27. The novel triazoloquinazoline and azoloquinolone scaffolds were designed de novo employing the pharmacophore model. A multigram-synthesis of the triazoloquinazoline 147 was developed and a library of ligands substituted on a position corresponding to the interface region was created. This study demonstrates the high predictive value of the developed benzodiazepine-binding site pharmacophore model and the utilization of de novo design of GABAA ligands. The hypothesis of the novel scaffolds, besides being potent, was they would allow for new substituent patterns in the benzodiazepine-binding site, and guided by molecular modelling, facilitate the development and understanding of GABAA subtype selective ligands. (Less)
Please use this url to cite or link to this publication:
author
supervisor
opponent
  • Grötli, Morten, Göteborgs Universitet
organization
publishing date
type
Thesis
publication status
published
subject
pages
120 pages
defense location
Sal C, Kemicentrum, Getingev 60, Lund
defense date
2008-05-29 09:30
ISBN
978-91-628-7518-3
language
English
LU publication?
yes
id
0fc461fd-c1f3-45c2-91bc-8fa1a224ba11 (old id 1146226)
date added to LUP
2008-05-06 14:49:54
date last changed
2016-09-19 08:45:18
@misc{0fc461fd-c1f3-45c2-91bc-8fa1a224ba11,
  abstract     = {Ligands for the benzodiazepine-binding site of the GABAA receptor can belong to structurally diverse classes of compounds including, in spite of the name of the binding site, many non-benzodiazepine structures. The GABAA receptor is a ligand-gated ion channel assembled of five subunits from eight different classes with multiple isoforms. The physiological effect elicited by benzodiazepines is believed to depend particularly on the isoform of the α-subunit. In this study new heterocyclic ligands were designed and synthesized from a pharmacophore model of the benzodiazepine-binding site partly developed in this study. The novel heterocyclic benzodiazepine receptor ligands synthesized include 4-quinolones, aza flavones, triazoloquinazolines, isoxazoloquinolones, pyrazoloquinolones, isothiazoloquinolones and isothiazolyl amides. All of these compound classes were active in vitro on the GABAA receptor with the 4-quinolone 72 displaying the highest affinity (Ki = 0.048 nM) so far reported. The 4-quinolones and the aza flavones all displayed selectivity for α1- versus α2- and α3-containing receptors, ranging from 2 to 27. The novel triazoloquinazoline and azoloquinolone scaffolds were designed de novo employing the pharmacophore model. A multigram-synthesis of the triazoloquinazoline 147 was developed and a library of ligands substituted on a position corresponding to the interface region was created. This study demonstrates the high predictive value of the developed benzodiazepine-binding site pharmacophore model and the utilization of de novo design of GABAA ligands. The hypothesis of the novel scaffolds, besides being potent, was they would allow for new substituent patterns in the benzodiazepine-binding site, and guided by molecular modelling, facilitate the development and understanding of GABAA subtype selective ligands.},
  author       = {Nilsson, Jakob},
  isbn         = {978-91-628-7518-3},
  language     = {eng},
  pages        = {120},
  title        = {The GABAA Receptor as Target for Novel Heterocyclic Compounds},
  year         = {2008},
}